Arcus Biosciences Q3 EPS $(1.00) Misses $(0.90) Estimate, Sales $9.000M Beat $8.305M Estimate
Benzinga Newsdesk 12 hours ago
NewsEarningsEarnings BeatsEarnings Misses
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.90) by 11.11 percent. This is a 21.26 percent increase over losses of $(1.27) per share
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.90) by 11.11 percent. This is a 21.26 percent increase over losses of $(1.27) per share from the same period last year. The company reported quarterly sales of $9.000 million which beat the analyst consensus estimate of $8.305 million by 8.36 percent. This is a 65.38 percent decrease over sales of $26.000 million the same period last year.